中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2011, Vol. 46 Issue (24) :1923-1928    DOI:
���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
�������Կڷ�����������͸�ҩ��������̬���ҩ��ѧ�������Ч������
���ж�1������Ƽ1��ʩТ��1��������2������1������1��������1
1. ������ѧ������ɽҽԺҩ�����ٴ�ҩѧ�о��ң��Ϻ� 200040��2. ������ѧҩѧԺ���Ϻ� 201203
LI Zhong-dong1��GUO Yan-ping1��SHI Xiao-jin1��YU Yun-qiu2��GENG Fang1��SHEN Min1��ZHONG Ming-kang1
1. Division of Clinical Pharmacy Research, Huashan Hospital,Fudan University,Shanghai 200040, China�� 2.School of Pharmacy, Fudan University , Shanghai 201203, China

Download: PDF (1187KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �����й�����־Ը�߿ڷ�3��������͸�ҩ�������������̬ҩ��ѧ�������Ч�ԡ����� ����Һ��ɫ��-����/���׷��ⶨ18�����������߿ڷ�3����������Ƽ���Ѫ���е��������Ũ�ȡ�����WinNonlinҩ���������ҩ��ѧ�������������������Ч�ԡ���� ����˫��Ϳ���Ƭ+��������Ƭ������ҩ1�������˿��Ƭ+��������Ƭ������ҩ2���Ϳ���˫��Ϳ���Ƭ���α�ҩ�����������ҩ��ѧ����AUC0-12�ֱ�Ϊ(3 657.57��683.27)����2 365.87��597.81����(3 017.48��612.99) ng��h��mL-1��ʵ����maxΪ(809.56��128.40)����742.50��152.81����(746.83��148.53) ng��mL-1��ʵ��tmaxΪ(2.53��0.50)����1.42��0.70����(2.19��0.71) h��MRT0-infΪ(6.57��2.15)����6.04��1.91����(6.75��2.80) h��t1/2Ϊ(2.96��1.04)����2.72��1.43����(2.87��1.12) h����������ͼƣ�����ҩ1�Ͳ���ҩ2��α�ҩ������������öȷֱ�Ϊ(128.77��47.69)%�ͣ�80.43��20.11��%������ ��ͳ��ѧ��������������ͼƣ�����ҩ1������ҩ2�ֱ�Ͳα�ҩ��Ⱦ����ﲻ��Ч������ҩ1������ҩ2��α�ҩ����max�������Ч�����Dz����Ⱥͼ��飬��α�ҩ��ȣ�����ҩ1��tmax���������죨P>0.05��������ҩ2���������죨P<0.05�����α�ҩtmax���ڲ���ҩ2��tmax��
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
���ж�1
����Ƽ1
ʩТ��1
������2
����1
����1
������1
���ж�1
����Ƽ1
ʩТ��1
������2
����1
����1
������1
�ؼ����� �������   ����ɭ��   Һ��ɫ�������÷�   �����Ч��   ҩ������ѧ   �������ö�     
Abstract�� OBJECTIVE To evaluate the steady-state pharmacokinetics and the bioequivalence of 3 oral compound levodopa preparations in 18 Chinese healthy male volunteers. METHODS Multiple oral doses of 3 compound levodopa preperations, i.e. test 1�� Sinemet CR tablet and entacapone tablet, test 2�� Madopar tablet and entacapone tablet, and reference�� Sinemet CR tablet, were given to 18 healthy volunteers in a randomized crossover study. The concentrations of levodopa were determined by HPLC-MS/MS method. RESULTS The main pharmacokinetic parameters of the 3 preparations were as follows�� AUC0-12(3 657.57��683.27), (2 365.87��597.81) and (3 017.48��612.99)ng��h��mL-1����max (809.56��128.40), ��742.50��152.81��and (746.83��148.53) ng��mL-1��tmax (2.53��0.50), ��1.42��0.70��and (2.19��0.71) h��MRT0-inf (6.57��2.15), ��6.04��1.91��and (6.75��2.80) h ��t1/2 (2.96��1.04), ��2.72��1.43��and (2.87��1.12) h��respectively. The relative bioavailability of test 1 and test 2 tablets to reference tablets were (128.77��47.69)% and��80.43��20.11��%��respectively. There were significant differences in the main pharmacokinetic parameters between the 3 preparations (P<0.05). CONCLUSION The RESULTS of statistical analysis demonstrated that the relative bioavailability of two test preparations were nonbioequivalent to the reference one, but their ��max were both bioequivalent to the reference tablets, and the tmax of test 1 had no difference with the reference (P>0.05), the tmax of the reference was greater than the one of test 2 (P<0.05) .
Keywords�� levodopa,   Parkinson��s disease,   LC-MS/MS,   bioequivalence,   bioavailability,   pharmacokinetics     
�ո�����: 2011-11-11;
���ñ���:   
���ж�1, ����Ƽ1, ʩТ��1�� .�������Կڷ�����������͸�ҩ��������̬���ҩ��ѧ�������Ч������[J]  �й�ҩѧ��־, 2011,V46(24): 1923-1928
LI Zhong-dong, GUO Yan-ping, SHI Xiao-jin etc .Study on the Steady-State Pharmacokinetics and Bioequivalence of Three Oral Compound Levodopa Preperations in Healthy Male Volunteers[J]  Chinese Pharmaceutical Journal, 2011,V46(24): 1923-1928
��
[1] PAIJA O�� LAINE K�� KULTALAHTI E R��et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with sinemet CR[J]. Clin Neuropharmcol��2005��28(3)��115-119.[2] AHTILA S, KAAKKOLA S, GORDIN A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa/carbidopa in volunteers[J]. Clin Neuropharmacol�� 1995,18��1����46-57.[3] PICCINI P, BROOKS D J, KORPELA K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson��s disease[J]. J Neurol Neurosurg Psychiatry�� 2000,68��5����589-594.[4] STOCCHI F, BARBATO L, NORDERA G, et al. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients[J]. J Neural Transm, 2004,111��2����173-180.[5] GORDIN A, KAAKKOLA S, TER�ZV�ZINEN H. Position of COMT inhibition in the treatment of Parkinson's disease[J]. Adv Neurol�� 2003,91��237-250.[6] KAAKKOLA S. Clinical pharmacology, therapeutics and potential of COMT inhibitors in Parkinson's disease[J]. Drugs�� 2000,59��6����1233-1250.[7] NUTT J G, WOODWARD W R, BEEKNER R M, et al. Effects of an inhibitor of catechol-O- methyltransferase (COMT) on the pharmacokinetics and pharmacodynamics of levodopa[J]. Neurology�� 1994,44��5����913-919[8] KAAKKOLA S, TER�ZV�ZINEN H, AHTILA S, et al. Entacapone in combination with standard or controlled release levodopa/carbidopa�� a clinical and pharmacokinetic study in patients with Parkinson's disease[J]. Eur J Neurol�� 1994,44(1)��77-80.[9] MUZZI C, BERTOCCI E, TERZUOLI L, et al. Simultaneous determination of serum concentrations of levodopa, dopamine, 3-O-methyldopa and a-methyldopa by HPLC[J]. Biomed Pharmacother, 2008,62(4)��253-258.[10] YEH K C, AUGUST T F, BUSH D F, et al. Pharmacokinetics and bioavailability of Sinemet CR�� a summary of human studies[J]. Neurology�� 1989,39(11 suppl 2)��25-38.
[1] ������ л�� ����� ����� ţ��ӱ.���������ڼ���CCl4�����˴����������������ڵ�ҩ������ѧ�Ƚ��о�[J]. �й�ҩѧ��־, 2012,47(7): 534-538
[2] ��С�� ��ӱ ��½�� κӱ�� ��ǿ ���.�������������������Ʊ�����������ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2012,47(7): 524-528
[3] �ܹ��� �պ� ��ȫӢ ���ı� ��ΰ��.һ��ҩԴ������ɭ�ۺ����ķ��������[J]. �й�ҩѧ��־, 2012,47(7): 565-566
[4] ½���� ׯ�꾲 ���.���׽��ҩ���о���չ[J]. �й�ҩѧ��־, 2012,47(7): 481-485
[5] ʩ���� ���� ���ļ� ��ȫӢ .����������͡��Ĥ��Ƭ�������Ч���о�[J]. �й�ҩѧ��־, 2012,47(5): 367-370
[6] ������ ����Ƽ ���ж� ʩТ�� ������.����Ī˾�����������ڵ������Ч������[J]. �й�ҩѧ��־, 2012,47(4): 296-302
[7] ���� �ܰ� ³���� ����ΰ.��ͬ��������������鶯���������պͷֲ��о�[J]. �й�ҩѧ��־, 2012,47(1): 44-48
[8] ���� �ņ��� ���ٻ� �ſ� ����� ������.������Ƭ�ڽ�������������Ч���о�[J]. �й�ҩѧ��־, 2011,46(9): 695-698
[9] ������ ������ ���׶� ���� ��־�� ţ���� ���̷� ��Ρ.����ɭ��ģ�ʹ���ѪҺ����״��ϸ����Һ�������ҩ��ѧͬ���о�[J]. �й�ҩѧ��־, 2011,46(8): 610-614
[10] ��ϼ ȫ����.����˫����������΢����ҩϵͳ������������[J]. �й�ҩѧ��־, 2011,46(8): 600-604
[11] �࿡�� ����� �Ŵ��� ������ ���� ������.���μ��հ������ҩ��ѧ�;����������ö��о�[J]. �й�ҩѧ��־, 2011,46(8): 615-618
[12] ��ʤ�� ������ ����� ��� ��Ӣ Ƚ���� ������.HPLC-UV�ⶨ����Ѫ���и�øQ10Ũ�ȼ��䶯̬�о�[J]. �й�ҩѧ��־, 2011,46(3): 224-227
[13] �Թ�� ������ ������ ������ .����鰷��������ɭ������Ч�ԺͰ�ȫ������[J]. �й�ҩѧ��־, 2011,46(23): 1847-1850
[14] ��� ��� ������ ��ܿ .CYP3A5�����̬�Զ��ٴ�ҩ������ѧӰ����о���չ[J]. �й�ҩѧ��־, 2011,46(20): 1541-1545
[15] ����� �ſ� ������ ���ٻ� ����÷ ���� �ņ���.�ɲ���ע��Һ�ڽ����������е�ҩ������ѧ�о�[J]. �й�ҩѧ��־, 2011,46(20): 1597-1600
Copyright 2010 by �й�ҩѧ��־